Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biodetection

    PATH, Mologic Team Up for Rapid Diagnostic to Support Malaria Elimination

    By Global Biodefense StaffMay 4, 2018
    Malaria Rapid Diagnostics
    Share
    Facebook LinkedIn Reddit Email

    PATH and Mologic have announced a new agreement to work together to advance a rapid diagnostic test to support treatment and elimination of Plasmodium vivax.

    More than 2.5 billion people worldwide are at risk of infection with P. vivax malaria, mainly in Southeast Asia and Latin America. P. vivax is especially difficult to eliminate because the parasite can lie dormant in the liver and re-emerge, causing periods of relapsing illness. With each relapse, patients become progressively sicker, and can continue to spread the disease through mosquitoes to other members of the community.

    Treatment with 8-aminoquinolines, a class of drugs that includes primaquine, is currently the only means to kill the liver form of the P. vivax parasite and prevent the cycle of relapse and transmission. However, 8-aminoquinolines can cause serious side effects in patients with severe glucose-6-phosphate dehydrogenase (G6PD) deficiency, a hereditary condition common to areas where malaria is found.

    Therefore, the World Health Organization recommends testing patients for the condition before administering treatment with primaquine. Critically, diagnostic tests currently on the market for G6PD deficiency are neither simple enough to support their widespread use in low-resource areas nor robust enough to be used in the hot, humid areas where malaria is endemic.

    PATH is advancing a portfolio of tests for G6PD deficiency that meet requirements for use in settings where P. vivaxmalaria is close to elimination. As part of this effort, PATH is working with Mologic to develop a novel qualitative point-of-care G6PD rapid diagnostic test (RDT).

    This new RDT has the potential to improve access to G6PD testing to support appropriate administration of primaquine. PATH and Mologic optimized the Mologic RDT for use in environmental conditions typical in malaria-endemic countries, resulting in a test that is designed for use including at the community level, where malaria is commonly diagnosed and treated. It provides simple results (i.e., positive or negative) that can be easily interpreted by test users to determine if a patient has severe G6PD deficiency and is therefore at increased risk for side effects if treated with primaquine.

    This qualitative G6PD RDT can provide a simple and affordable alternative to quantitative tests, which provide a numerical readout of G6PD levels but may be more expensive.

    “This test will be a significant addition to the G6PD testing options available to health care providers to inform case management of patients with P. vivax malaria. It will help to fill critical gaps in G6PD testing experienced by elimination programs, and will complement quantitative tests for G6PD deficiency being advanced by PATH and partners.” – Dr. Gonzalo Domingo, scientific director and malaria diagnostics lead at PATH.

    The first product variant is expected to come to market in 2019. PATH is supporting Mologic to commercialize the RDT and obtain key regulatory approvals.

    Funding to PATH to support advancement of new G6PD diagnostic tools has been provided by UKAid from the United Kingdom Department for International Development and the Bill & Melinda Gates Foundation.

    Sources: PATH, Mologic, PRNewswire

    Malaria Rapid Diagnostics
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleNerve Agent Therapeutics, CRISPR Oversight, Pandemic Influenza Preparedness
    Next Article Novel Algorithm Approach to Fight the Spread of Diseases

    Related Stories

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    Biomarkers for Detection of Exposure to Nitrogen Mustards

    September 20, 2023

    Mass Spec for Rapid Detection of Biological Warfare Agents

    September 15, 2023

    Field Detection of Botulinum Neurotoxin with Acoustic Wave Sensors

    September 15, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    Oct 17
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Dispensing and Administration of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.